Sunday, September 14, 2014 6:25:57 AM
Why does the FDA put hurdles on our small biotech company??? Why find the toxic dose? FDA could have requested the toxic dose for later and that would have been ok. All of this while you see vaccine makers getting all kinds of taxpayers money and I am referring to big cap companies in comparison to our small biotech. And how generous of some companies/governments to donate vaccine doses that were made possible/manufactured with taxpayers money. It is as if they were saying, "...use those vaccine doses quickly because if the virus mutates they will become worthless...". And whatever happened with Tamiflu data? Billions were spent by governments just to find out later that the vaccine was marginally effective.
The PEG molecule is common to all nanoviricides, yes? The difference among nanoviricides What products are out there in the market with PEG that have been, by FDA regulations, required to undergo clinical studies. What were their results and are they in the market today? Perhaps it may be easier to cite the failures, if any.
If EbolaCide tests in BSL-4 facility and if found to be highly efficient, why not employ it right away to fight Ebola? How far did Zmapp go, in meeting goals according to FDA regulations, before it was employed in the US and in Liberia, Africa?
If we are not delayed for FluCide, we are not delayed for 2015. Why would any one say "not delayed" and skip the entire 2015? You said it in one of your posts, time will wait for no one, not even NNVC.
Thirteen weeks (13 weeks)? We are advancing with FluCide in paralell to EbolaCide. Are FluCide GLP full tox studies worth anything in relation to EbolaCide and FDA regulations/requirements?
I don't have the time to post any other questions this morning. Perhaps in the evening.
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
FEATURED Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • May 17, 2024 11:00 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM